Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

miR-500a-5p regulates oxidative stress response genes in breast cancer and predicts cancer survival

(2017) Davide Degli Esposti et al.   Scientific Reports

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

(2016) David J. McConkey et al.   EUROPEAN UROLOGY

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer

(2016) Andrea E. Ochoa et al.   Oncotarget

Expression of bone morphogenetic protein-2 and -7 in urinary bladder cancer predicts time to tumor recurrence

(2015) Bolesław Kuzaka et al.   Archives of Medical Science

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL

(2014) QI SUN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

MicroRNA let-7g and let-7i inhibit hepatoma cell growth concurrently via downregulation of the anti-apoptotic protein B-cell lymphoma-extra large

(2014) LINGJIAO WU et al.   Oncology Letters

Emetine Dihydrochloride: A Novel Therapy for Bladder Cancer

(2013) Kimberly E. Foreman et al.   JOURNAL OF UROLOGY

The evolving understanding of microRNA in bladder cancer

(2013) Elizabeth A. Guancial et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer

(2012) Markus Riester et al.   CLINICAL CANCER RESEARCH

MicroRNA and cancer

(2012) Martin D. Jansson et al.   Molecular Oncology

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries

(2012) Gavriel Mullokandov et al.   NATURE METHODS

Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma

(2012) David Lindgren et al.   PLoS One

MicroRNAs as regulators of epithelial-mesenchymal transition

(2011) Philip A. Gregory et al.   CELL CYCLE

Emerging Roles for Natural MicroRNA Sponges

(2010) Margaret S. Ebert et al.   CURRENT BIOLOGY

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

(2010) Christina Barbara Ching et al.   LABORATORY INVESTIGATION

Target mRNA abundance dilutes microRNA and siRNA activity

(2010) Aaron Arvey et al.   Molecular Systems Biology

The widespread regulation of microRNA biogenesis, function and decay

(2010) Jacek Krol et al.   NATURE REVIEWS GENETICS